Do analysts recommend TPST or PLRX?

Pliant Therapeutics has a consensus price target of $3.00, indicating a potential upside of 163.16%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Pliant Therapeutics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is TPST or PLRX more profitable?

Pliant Therapeutics' return on equity of -58.11% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% Pliant Therapeutics N/A -58.11% -44.37%

Do analysts recommend HYFT or TPST?

MindWalk presently has a consensus target price of $5.00, suggesting a potential upside of 216.46%. Given MindWalk's stronger consensus rating and higher probable upside, research analysts plainly believe MindWalk is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MindWalk 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate TPST or XBIT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, TPST or XBIT?

XBiotech is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A XBiotech N/A N/A -$45.54M -$1.32 N/A

Is TPST or XBIT more profitable?

XBiotech's return on equity of -26.10% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% XBiotech N/A -26.10% -25.06%

Do analysts rate TPST or EXOZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TPST or EXOZ more profitable?

eXoZymes' return on equity of -220.63% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% eXoZymes N/A -220.63% -141.26%

Do analysts prefer TPST or CING?

Cingulate has a consensus price target of $27.33, indicating a potential upside of 399.70%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation & earnings, TPST or CING?

Cingulate is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A Cingulate N/A N/A -$22.45M -$4.23 N/A

Is TPST or CING more profitable?

Tempest Therapeutics' return on equity of -355.61% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% Cingulate N/A -365.15% -158.55%

Tempest Therapeutics (TPST) Competitors

$1.11 +0.01 (+0.91%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$1.12 +0.01 (+0.54%)

As of 09:02 AM Eastern

Compare

TPST vs. PLRX, HYFT, XBIT, EXOZ, and CING

Should you buy Tempest Therapeutics stock or one of its competitors? MarketBeat compares Tempest Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tempest Therapeutics include Pliant Therapeutics (PLRX), MindWalk (HYFT), XBiotech (XBIT), eXoZymes (EXOZ), and Cingulate (CING). These companies are all part of the "pharmaceutical products" industry.

How does Tempest Therapeutics compare to Pliant Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Tempest Therapeutics and Tempest Therapeutics both had 2 articles in the media. Tempest Therapeutics' average media sentiment score of 1.43 beat Pliant Therapeutics' score of 0.94 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Positive
Pliant Therapeutics	Positive

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 36.3% of Tempest Therapeutics shares are held by company insiders. Comparatively, 6.4% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pliant Therapeutics has a consensus price target of $3.00, indicating a potential upside of 163.16%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Pliant Therapeutics' return on equity of -58.11% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Tempest Therapeutics has a beta of -1.85, meaning that its share price is 285% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

Tempest Therapeutics has higher earnings, but lower revenue than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Pliant Therapeutics	$1.58M	44.68	-$149.34M	-$1.84	N/A

Summary

Pliant Therapeutics beats Tempest Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Tempest Therapeutics compare to MindWalk?

MindWalk (NASDAQ:HYFT) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

MindWalk has higher revenue and earnings than Tempest Therapeutics. MindWalk is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	4.15	-$21.69M	-$0.20	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

In the previous week, MindWalk and MindWalk both had 2 articles in the media. MindWalk's average media sentiment score of 1.87 beat Tempest Therapeutics' score of 1.43 indicating that MindWalk is being referred to more favorably in the media.

Company	Overall Sentiment
MindWalk	Very Positive
Tempest Therapeutics	Positive

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 36.3% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MindWalk presently has a consensus target price of $5.00, suggesting a potential upside of 216.46%. Given MindWalk's stronger consensus rating and higher probable upside, research analysts plainly believe MindWalk is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

MindWalk has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, meaning that its stock price is 285% less volatile than the broader market.

Tempest Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. MindWalk's return on equity of -69.37% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Summary

MindWalk beats Tempest Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Tempest Therapeutics compare to XBiotech?

Tempest Therapeutics (NASDAQ:TPST) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

XBiotech is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

In the previous week, Tempest Therapeutics and Tempest Therapeutics both had 2 articles in the media. Tempest Therapeutics' average media sentiment score of 1.43 beat XBiotech's score of 1.27 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Positive
XBiotech	Positive

Tempest Therapeutics has a beta of -1.85, indicating that its share price is 285% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 36.3% of Tempest Therapeutics shares are owned by insiders. Comparatively, 30.8% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

XBiotech's return on equity of -26.10% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
XBiotech	N/A	-26.10%	-25.06%

Summary

Tempest Therapeutics and XBiotech tied by winning 5 of the 10 factors compared between the two stocks.

How does Tempest Therapeutics compare to eXoZymes?

Tempest Therapeutics (NASDAQ:TPST) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Tempest Therapeutics has a beta of -1.85, meaning that its stock price is 285% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.65, meaning that its stock price is 165% more volatile than the broader market.

eXoZymes' return on equity of -220.63% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
eXoZymes	N/A	-220.63%	-141.26%

22.5% of Tempest Therapeutics shares are held by institutional investors. 36.3% of Tempest Therapeutics shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Tempest Therapeutics and Tempest Therapeutics both had 2 articles in the media. Tempest Therapeutics' average media sentiment score of 1.43 beat eXoZymes' score of 1.19 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Positive
eXoZymes	Positive

eXoZymes has higher revenue and earnings than Tempest Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
eXoZymes	$70K	1,021.23	-$9.16M	-$1.14	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

eXoZymes beats Tempest Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Tempest Therapeutics compare to Cingulate?

Tempest Therapeutics (NASDAQ:TPST) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Tempest Therapeutics' return on equity of -355.61% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Cingulate	N/A	-365.15%	-158.55%

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 36.3% of Tempest Therapeutics shares are owned by insiders. Comparatively, 5.3% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cingulate has a consensus price target of $27.33, indicating a potential upside of 399.70%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cingulate had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 3 mentions for Cingulate and 2 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.43 beat Cingulate's score of 1.05 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Positive
Cingulate	Positive

Tempest Therapeutics has a beta of -1.85, indicating that its share price is 285% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.85, indicating that its share price is 185% less volatile than the broader market.

Cingulate is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

Summary

Cingulate beats Tempest Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TPST vs. The Competition

Export

Metric	Tempest Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.58M	$3.08B	$7.07B	$12.45B
Dividend Yield	N/A	1.86%	2.66%	6.16%
P/E Ratio	-0.18	19.38	27.24	24.87
Price / Sales	N/A	350.27	542.17	102.84
Price / Cash	N/A	57.53	48.53	58.59
Price / Book	0.82	4.28	10.95	6.54
Net Income	-$26.26M	$64.45M	$3.57B	$336.70M
7 Day Performance	-4.31%	3.22%	2.27%	2.81%
1 Month Performance	-23.45%	2.23%	1.35%	0.59%
1 Year Performance	-83.91%	34.37%	36.71%	31.29%

Tempest Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TPST Tempest Therapeutics	1.9185 of 5 stars	$1.11 +0.9%	N/A	-83.7%	$17.58M	N/A	N/A	20	Positive News Short Interest Decrease
PLRX Pliant Therapeutics	2.6778 of 5 stars	$1.16 flat	$3.00 +158.6%	-1.7%	$71.83M	$1.58M	N/A	90
HYFT MindWalk	3.1558 of 5 stars	$1.50 -2.0%	$5.00 +233.3%	N/A	$70.62M	$17.59M	N/A	80	Positive News
XBIT XBiotech	0.7315 of 5 stars	$2.31 flat	N/A	-22.6%	$70.43M	N/A	N/A	100	News Coverage
EXOZ eXoZymes	0.9119 of 5 stars	$8.18 +4.5%	N/A	-14.7%	$69.36M	N/A	N/A	29	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TPST) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tempest Therapeutics (TPST) Competitors

TPST vs. PLRX, HYFT, XBIT, EXOZ, and CING

How does Tempest Therapeutics compare to Pliant Therapeutics?

Summary

How does Tempest Therapeutics compare to MindWalk?

Summary

How does Tempest Therapeutics compare to XBiotech?

Summary

How does Tempest Therapeutics compare to eXoZymes?

Summary

How does Tempest Therapeutics compare to Cingulate?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tempest Therapeutics (TPST) Competitors

TPST vs. PLRX, HYFT, XBIT, EXOZ, and CING

How does Tempest Therapeutics compare to Pliant Therapeutics?

Does the media prefer TPST or PLRX?

Do institutionals & insiders believe in TPST or PLRX?

Do analysts recommend TPST or PLRX?

Is TPST or PLRX more profitable?

Which has more risk and volatility, TPST or PLRX?

Which has stronger earnings and valuation, TPST or PLRX?

Summary

How does Tempest Therapeutics compare to MindWalk?

Which has higher earnings and valuation, HYFT or TPST?

Does the media favor HYFT or TPST?

Do institutionals and insiders hold more shares of HYFT or TPST?

Do analysts recommend HYFT or TPST?

Which has more risk & volatility, HYFT or TPST?

Is HYFT or TPST more profitable?

Summary

How does Tempest Therapeutics compare to XBiotech?

Which has higher earnings and valuation, TPST or XBIT?

Does the media prefer TPST or XBIT?

Which has more volatility and risk, TPST or XBIT?

Do analysts rate TPST or XBIT?

Do insiders and institutionals believe in TPST or XBIT?

Is TPST or XBIT more profitable?

Summary

How does Tempest Therapeutics compare to eXoZymes?

Which has more risk & volatility, TPST or EXOZ?

Is TPST or EXOZ more profitable?

Do institutionals & insiders hold more shares of TPST or EXOZ?

Does the media refer more to TPST or EXOZ?

Which has stronger earnings & valuation, TPST or EXOZ?

Do analysts rate TPST or EXOZ?

Summary

How does Tempest Therapeutics compare to Cingulate?

Is TPST or CING more profitable?

Do insiders and institutionals have more ownership in TPST or CING?

Do analysts prefer TPST or CING?

Does the media prefer TPST or CING?

Which has more risk & volatility, TPST or CING?

Which has stronger valuation & earnings, TPST or CING?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools